Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination?

Marsh K, Chapman R, Baggaley RF, Largeron N, Bresse X.

Vaccine. 2014 Jun 24;32(30):3732-9. doi: 10.1016/j.vaccine.2014.05.007. Epub 2014 May 15. Review.

PMID:
24837538
2.

Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.

Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ.

Vaccine. 2014 Mar 26;32(15):1645-53. doi: 10.1016/j.vaccine.2014.01.058. Epub 2014 Feb 15. Review.

PMID:
24534737
3.

A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.

Jiang Y, Gauthier A, Postma MJ, Ribassin-Majed L, Largeron N, Bresse X.

Hum Vaccin Immunother. 2013 Nov;9(11):2285-95. Epub 2013 Jul 23. Review.

4.

Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples.

Postma MJ, Westra TA, Quilici S, Largeron N.

Expert Rev Vaccines. 2013 May;12(5):555-65. doi: 10.1586/erv.13.36. Review.

PMID:
23659302
5.

Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review.

Préaud E, Largeron N.

J Med Econ. 2013;16(6):763-76. doi: 10.3111/13696998.2013.793691. Epub 2013 Apr 24. Review.

PMID:
23565814
6.

A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.

Bresse X, Adam M, Largeron N, Roze S, Marty R.

Hum Vaccin Immunother. 2013 Apr;9(4):823-33. doi: 10.4161/hv.22994. Epub 2013 Apr 1.

7.

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.

Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J.

BMC Cancer. 2013 Jan 8;13:10. doi: 10.1186/1471-2407-13-10.

8.

Cost–effectiveness of catch-up programs in human papillomavirus vaccination.

de Peuter MA, Littlewood KJ, Annemans L, Largeron N, Quilici S.

Expert Rev Vaccines. 2010 Oct;9(10):1187-201. doi: 10.1586/erv.10.108. Review.

PMID:
20923269
9.

Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain.

Diez-Domingo J, Suriñach NL, Alcalde NM, Betegón L, Largeron N, Trichard M.

BMC Public Health. 2010 Aug 10;10:469. doi: 10.1186/1471-2458-10-469.

10.

Incidence of invasive cervical cancer and direct costs associated with its management in Italy.

Ricciardi A, Largeron N, Giorgi Rossi P, Raffaele M, Cohet C, Federici A, Palazzo F.

Tumori. 2009 Mar-Apr;95(2):146-52.

PMID:
19579858
11.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
12.

Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.

Giorgi Rossi P, Ricciardi A, Cohet C, Palazzo F, Furnari G, Valle S, Largeron N, Federici A.

BMC Public Health. 2009 Feb 25;9:71. doi: 10.1186/1471-2458-9-71.

13.

Health and economic impact associated with a quadrivalent HPV vaccine in Italy.

Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N.

Gynecol Oncol. 2009 Feb;112(2):370-6. doi: 10.1016/j.ygyno.2008.09.031. Epub 2008 Nov 28.

PMID:
19041125
14.

Treatment patterns and associated costs for genital warts in Italy.

Merito M, Largeron N, Cohet C, Timelli L, Boselli F, Matteelli A, Naldi L, Vittori G.

Curr Med Res Opin. 2008 Nov;24(11):3175-83. doi: 10.1185/03007990802485694 . Epub 2008 Oct 10.

PMID:
18851777
15.

Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model.

Dasbach EJ, Largeron N, Elbasha EH.

Expert Rev Pharmacoecon Outcomes Res. 2008 Oct;8(5):491-500. doi: 10.1586/14737167.8.5.491.

PMID:
20528334
16.

[Economic evaluation of acute paediatric rotavirus gastroenteritis in France].

Huet F, Allaert FA, Trancart A, Miadi-Fargier H, Trichard M, Largeron N.

Arch Pediatr. 2008 Jul;15(7):1159-66. doi: 10.1016/j.arcped.2008.04.009. Epub 2008 Jun 3. French.

PMID:
18524550
17.

[Epidemiology and burden of rotavirus diarrhea in day care centers in Lyon, France].

Fau C, Billaud G, Pinchinat S, Lina B, Kaplon J, Pothier P, Derrough T, Marcelon L, Largeron N, Caulin E, Bellemin B, Cao Nong T, Gaspard C, Mamoux V, Floret D.

Arch Pediatr. 2008 Jul;15(7):1183-92. doi: 10.1016/j.arcped.2008.02.016. Epub 2008 May 5. French.

PMID:
18456480
18.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
19.

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.

Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER.

Cost Eff Resour Alloc. 2008 Feb 15;6:4. doi: 10.1186/1478-7547-6-4.

20.

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.

Int J Technol Assess Health Care. 2008 Winter;24(1):10-9. doi: 10.1017/S0266462307080026.

PMID:
18218164
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk